Illumina, Inc. $ILMN Holdings Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 232,646 shares of the life sciences company’s stock after purchasing an additional 17,519 shares during the quarter. Russell Investments Group Ltd.’s holdings in Illumina were worth $63,651,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ILMN. Eurizon Capital SGR S.p.A. lifted its holdings in Illumina by 12.1% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 19,801 shares of the life sciences company’s stock valued at $5,416,000 after purchasing an additional 2,132 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of Illumina by 17.5% during the third quarter. Maryland State Retirement & Pension System now owns 9,269 shares of the life sciences company’s stock worth $2,537,000 after buying an additional 1,379 shares in the last quarter. Advisor Resource Council purchased a new stake in shares of Illumina during the third quarter worth $264,000. Ritholtz Wealth Management raised its position in shares of Illumina by 288.1% in the third quarter. Ritholtz Wealth Management now owns 5,682 shares of the life sciences company’s stock valued at $1,555,000 after buying an additional 4,218 shares during the last quarter. Finally, Jefferies Financial Group Inc. raised its position in shares of Illumina by 217.2% in the third quarter. Jefferies Financial Group Inc. now owns 8,000 shares of the life sciences company’s stock valued at $2,189,000 after buying an additional 5,478 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Illumina

In other news, Director Keith Meister sold 98,833 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the sale, the director owned 208,826 shares in the company, valued at $45,288,094.62. This trade represents a 32.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Scott Ericksen sold 267 shares of Illumina stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total transaction of $58,141.92. Following the sale, the chief accounting officer directly owned 14,029 shares in the company, valued at approximately $3,054,955.04. The trade was a 1.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,881,899 shares of company stock valued at $415,905,954. Corporate insiders own 2.90% of the company’s stock.

Illumina News Summary

Investors following ILMN have been watching these news items:

• Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
• Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
• Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ILMN shares. Evercore reissued an “underperform” rating on shares of Illumina in a research note on Friday, October 30th. TD Cowen upped their price objective on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Barclays increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. Leerink Partners raised their target price on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, Deutsche Bank lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $244.24.

Illumina Trading Down 1.2%

Shares of ILMN traded down $2.54 during mid-day trading on Friday, reaching $207.01. The stock had a trading volume of 1,229,158 shares, compared to its average volume of 2,291,458. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The business’s fifty day moving average is $249.02 and its 200 day moving average is $179.64. The firm has a market cap of $31.30 billion, a price-to-earnings ratio of 35.63, a P/E/G ratio of 2.84 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, sell-side analysts predict that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.